logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin us
 

News

boto imprimir
Date: 15/02/2016

A new therapeutic strategy for more aggressive lung tumor


Lung cancer is one of the most prevalent, with more than 20,000 new cases diagnosed each year in Spain. In 30% intervenes KRAS oncogene, which causes more aggressive tumor. It is also a type of lung cancer that does not has targeted therapies beyond the standard cisplatin.

 

A study led by researchers Mariano Barbacid and David Santamaia, from the National Cancer Research Centre (CNIO), and which has also involved a team from ICO-IDIBELL formed by Alberto Villanueva and Ernest Nadal, has identified a possible new strategy for deal with these tumors.

 

The study, which was done in mouse models, is published in the journal Nature Medicine and shows how the combination of drugs dasatinib –inhibitor of DDR1- and demcizumab –an antibody that inhibits Notch pathway- specifically and effectively reduces tumors and improves prognosis and survival. Completed preclinical studies, the next step is to do clinical trials to validate the combination of these drugs for the treatment of lung adenocarcinomas.

 

The study's authors used preclinical models of genetically modified mouse. They have also been studied in orthoxenografts® of lung cancer orthotopic models that are generated by the implementation of human tumors in the mouse lung, generated by the team lead by Alberto Villanueva at ICO-IDIBELL / Xenopat S.L. These, the most advanced models on lung cancer, allow us to study the effectiveness of the drugs directly on human specimens.





Share/Bookmark
 
© 2016 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola de compres i contractacions. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell